Exosomes are cell-secreted vesicles with diameters ranging from 30 to 150 nm, widely distributed in blood, urine, and other body fluids. Rich in proteins, RNA, and lipids, exosomes serve as critical mediators of intercellular signaling and play significant roles in disease diagnosis, drug target identification, and therapeutic research. With advances in mass spectrometry, high-throughput and precise protein quantification methods have become essential tools for exosome research. Among these, Tandem Mass Tag (TMT) labeling and Data-Independent Acquisition (DIA) technologies have gained considerable attention due to their high sensitivity, reproducibility, and proteome coverage.

Core Significance of Quantitative Exosome Proteomics

Quantitative exosome proteomics not only provides insights into cellular states but also facilitates the identification of disease-associated biomarkers, drug targets, and intercellular communication networks. Given the small sample volumes and the abundance of low-expression proteins in exosomes, high-sensitivity and broad-coverage quantification methods are particularly critical.

The advantages of TMT and DIA technologies in this context are as follows:

• TMT: Enables simultaneous quantification of multiple samples, allowing direct comparison across different treatment conditions or disease states.
• DIA: Provides high reproducibility and comprehensive coverage, making it especially suitable for systematic analysis of complex biological samples.

Exosome Sample Preparation and Protein Extraction

High-quality exosome sample preparation is crucial prior to TMT/DIA quantification. The main procedures include:

1. Exosome Isolation

Commonly employed methods include:

• Ultracentrifugation: Sequential centrifugation removes cellular debris and larger particles to obtain precipitated exosomes.
• Density Gradient Centrifugation: Utilizing sucrose or iodixanol gradients enhances purity, suitable for proteomic analysis.
• Immunoaffinity Capture: Exosomes are selectively captured using CD63, CD9, or CD81 antibodies, suitable for detecting low-abundance proteins.

2. Protein Extraction

Due to the limited protein content of exosomes, high-efficiency lysis buffers containing detergents and protease inhibitors are employed to:

• Ensure complete solubilization of membrane proteins.
• Preserve protein post-translational modifications.

3. Protein Quantification

Accurate protein quantification is typically performed using the BCA or Bradford assays to provide precise input for subsequent TMT or DIA analysis.

Figure 1. Exosome preparations for TMT or DIA quantification begin with isolation, efficient protein extraction, and accurate protein input measurement.

1. Principle

TMT is an isotopic labeling technique that chemically modifies peptide N-termini or lysine residues to enable relative quantification of multiple samples. Each tag has an identical mass-to-charge ratio (m/z) but releases distinct reporter ion signals upon mass spectrometry fragmentation, which are used for comparative quantification.

2. Workflow

• Protein Digestion: Proteins are enzymatically cleaved into peptides, commonly using trypsin.
• Peptide Labeling: Peptides from each experimental group are reacted with distinct TMT tags.
• Sample Mixing: Labeled peptides are combined and analyzed using LC-MS/MS.
• Mass Spectrometry Analysis: High-resolution Orbitrap or Q-Exactive systems are employed for DDA (Data-Dependent Acquisition) data collection.
• Data Interpretation: Database searching and reporter ion quantification provide relative quantification results across multiple samples.

3. Advantages and Applications

• Simultaneous analysis of 6-18 samples reduces mass spectrometry run times.
• Mitigates batch effects and enhances experimental reproducibility.
• Applicable to clinical sample comparisons, drug treatment studies, and disease stratification research.

Extended TMT labeling and acquisition steps are summarized in Workflow for TMT-labeled Quantitative Mass Spectrometry.

1. Principle

DIA is a non-selective acquisition approach in which all peptides within predefined mass windows are continuously scanned, achieving comprehensive “full-spectrum” acquisition. Using peptide libraries or direct spectral analysis, DIA enables highly efficient and accurate protein quantification.

2. Workflow

• Protein Digestion and Peptide Preparation: Conducted similarly to TMT but without labeling.
• Liquid Chromatography Separation: Complex peptide mixtures are separated prior to mass spectrometry analysis.
• DIA Acquisition: All peptide signals are acquired continuously within preset mass windows.
• Data Analysis: Software such as Spectronaut or DIA-NN is used to identify and quantify proteins.

3. Advantages and Applications

• High reproducibility, suitable for multi-batch analyses.
• Label-free approach, advantageous for low-abundance proteins.
• Deep proteome coverage, including low-abundance and membrane proteins.
• Supports time-series experiments, treatment comparisons, and complex disease models.

Acquisition, library strategy, and DIA data analysis steps are outlined in DIA Proteomics Workflow: Acquisition, Library Strategy and Data Analysis.

Figure 2. After exosome protein extraction, projects may follow a TMT labeling path or a label-free DIA acquisition path for relative quantification.

Data Analysis and Biological Interpretation

Quantitative exosome proteomics data require comprehensive analysis, including:

1. Protein Identification and Quantification: Performed using the UniProt database and software such as MaxQuant or Spectronaut.
2. Statistical Analysis: Includes differential protein screening, clustering, and PCA visualization.
3. Functional Annotation: GO enrichment, KEGG pathway analysis, and protein-protein interaction network construction.
4. Clinical or Mechanistic Correlation: Integration with disease phenotypes or drug treatment results to identify potential biomarkers or mechanistic insights.

Figure 3. Exosome proteomics interpretation typically combines identification, statistics, pathway annotation, and phenotype or treatment correlation.

Quantitative exosome proteomics using TMT and DIA provides a powerful platform for biomarker discovery, elucidation of drug mechanisms, and regenerative medicine research. MtoZ Biolabs integrates TMT and DIA technologies to deliver optimized end-to-end exosome proteomics services, covering sample preparation through data analysis, ensuring high sensitivity and reproducibility. With ongoing technological advancements, quantitative exosome proteomics is poised to play an increasingly pivotal role in precision medicine, early cancer detection, and personalized therapy. Researchers can also review the MtoZ Biolabs Exosome Protein Analysis Service for project-specific exosome isolation, TMT or DIA quantification planning, and data analysis support.